

This document is commercially sensitive, private and confidential and may not be disclosed to any third party without prior consent.


2020



Clinical Trials
Intelligence

Pre-Sale Funding Rounds

CTI Token Sale



– Introduction

Problem

Approach

Potential

About us

offer

Projections

Roadmap

Team

Partners

Information

ClinTex is a solution provider to the pharmaceutical industry with a mission to lower the cost of medicine, through lowering the cost of medicine development.

Clinical Trials Intelligence is a new collaboration platform from ClinTex that utilises the advantages of blockchain and decentralised ledger technology, to manage and optimise the key pain points during clinical trials.

Clinical Trials Intelligence will be first to market in its application of predictive analytics and machine learning to medicines development. It has been designed from the ground up to optimise clinical trial processes by providing the tools to streamline operational efficiency, clinical data quality, data collaboration and medical review.

By reducing development costs for the global pharmaceutical industry and removing the barriers caused by both delay and a lack of clinical data sharing, the ClinTex vision is that patients with unmet medical need will have expedited and cost-efficient access to new and promising medicines.

The Clinical Trials Intelligence platform hosts 7 applications, the primary function of which will be to drive clinical trial efficiency and target specific pain points through the use of clinical data analytics, machine learning and decentralised ledger technology.

- Introduction
- Problem**
- Approach
- Potential
- About us
- Offer
- Projections
- Roadmap
- Team
- Partners
- Information

Clinical Trials Intelligence will overcome the growing inefficiencies and quality issues that arise during clinical trials.



Operational inefficiencies

Clinical Trials are inefficient in their use of funding and resources. The median cost of advancing a single drug from concept to market is estimated at nearly \$3 billion.

[\(Source: Journal of Health Economics, May 2016\).](#)



Time to Market

ClinicalTrials.gov currently lists 335,576 studies with locations in all 50 U.S. States and in 210 countries worldwide. This is a significant increase from the 2,119 that were registered in 2000.



Reactive Management

Operational and clinical inefficiencies of trials are identified after they occur.



Recruitment and Retention

Difficulty in patient recruitment and retention results in 80% of clinical trials being delayed by an average of 10.8 months.



Poor Data Quality

Inadequate and incomplete data is a major cause of clinical trial failure.



Administrative Burden

Identification of and payments to third party vendors can delay clinical trial initiation and timely progression.


- Introduction
- Problem**
- Approach
- Potential
- About us
- Offer
- Projections
- Roadmap
- Team
- Partners
- Information

\$8,000,000
Up to per day

The loss in revenue opportunity
when a trial is delayed.

[Source: Praxis Report: Real Cost of Clinical Trials, 2017](#)


- Introduction
- Problem
- Approach
- Potential
- About us
- Offer
- Projections
- Roadmap
- Team
- Partners
- Information




PatientCentra

Could Data Inefficiencies Be Crippling Your Clinical Trial Outcomes?

Stempel | 3 Minute read



NBC NEWS



Pfizer fiasco shows drug makers must change

High cost of research and development is hurting companies



Forbes

October 16, 2017, 10:58am EDT

The Cost Of Developing Drugs Is Insane. That Paper That Says Otherwise Is Insanely Bad

Matthew Herper Former Staff, Healthcare



CLINICAL LEADER

April 25, 2019

Getting A handle On Clinical Trial Costs

Amit Pratap Singh Rathore, principal analyst, Beroe Inc.



JAMA Network

July 12, 2018

Delays in the Publication of Important Clinical Trial Findings in Oncology

Matthew Herper Former Staff, Healthcare



ClinTex Clinical Trials Intelligence – A Real-World Solution

Introduction
 Problem
 – Approach
 Potential
 About us
 Offer
 Projections
 Roadmap
 Team
 Partners
 Information

The Clinical Trials Intelligence Platform consists of 7 applications that specifically target the key pain points of clinical trials, incorporating blockchain and machine learning into the end-to-end clinical trial process for the very first time.



APPLICATION

CTi-OEM

*Operational
Excellence*

Providing data driven insight into waste minimisation in clinical trials.



APPLICATION

CTi-PDA

*Predictive
Analytics*

Using historical clinical trial data to predict future performance and proactively address issues before they arise.



APPLICATION

CTi-PRR

*Patient Recruitment
and Retention*

Selecting the right patient and help to ensure patient completes clinical trial by monitoring patient activity and alerting when patient is at risk.



APPLICATION

CTi-SIM

*Site
Investigators*

Identifying and recruiting medics to conduct clinical trials, and managing payments for their participation.



APPLICATION

CTi-VMM

*Vendor
Management*

Managing data quality from clinical trial vendors e.g. labs and third party payments based on data driven KPIs.



APPLICATION

CTi-RBM

*Risk Based
Monitoring*

In stream monitoring of data in order to ensure resource is efficiently deployed to areas of greatest risk.



APPLICATION

CTi-CDV

*Clinical Data
Visualisation*

Providing medics with visual analytics and dashboards to support faster decision making.

ClinTex Clinical Trials Intelligence – The Blockchain Use Case

Introduction
Problem
– Approach
Potential
About us
Offer
Projections
Roadmap
Team
Partners
Information

Audit trails are a critical procedure when working with clinical data.

The FDA and other regulatory authorities need to be able to verify the quality and integrity of the data (FDA, 2017) and a pharmaceutical company must, in accordance with Good Clinical Practice (GCP), record all changes to the data, who made the changes, and the date when the changes were made.

Our blockchain ledger is the perfect record keeping tool for this use case, because it does exactly that – with optimum tamperproof security.



Further capitalising on the immutable nature of distributed ledger technology, the Clinical Trials Intelligence blockchain functions as a secure complete recorded history of all clinical data views, whilst protecting underlying raw data.

This allows for the creation and evolution of a clinical insights database, which is then used to enable Clinical Trials Intelligence’s machine learning algorithms.

Smart contracts also enable Clinical Trials Intelligence to perform the secure execution of contracts based on triggers and milestones in the clinical data. For example, payment to an investigator can be automatically triggered as pre-set milestones are reached based on data entered.



Clinical Trials
Intelligence



Market Potential

Introduction
Problem
Approach
– **Potential**
About us
Offer
Projections
Roadmap
Team
Partners
Information

The Global Drug Development market is worth >\$350 billion per annum. The median cost of advancing a single drug from concept to market is estimated at nearly \$3 billion (\$2,870 million in 2013).

Source: Global Drug Discovery Market 2019-2027, Triton Market Research

Efficiency savings of 1%, applied to just 1% of global clinical trials, has the potential to deliver >\$35 million savings per annum.

This data excludes any impact from Covid-19, as robust metrics are not yet available.

The global drug discovery market is estimated to show exponential revenue growth during the period 2019-2027 at a CAGR of 8.28%. Asia-Pacific is the fastest-growing among the region.

- Introduction
- Problem
- Approach
- Potential
- About us
- Offer
- Projections
- Roadmap
- Team
- Partners
- Information

Purpose

ClinTex exists to transform human health through enabling pharma companies to improve clinical trials and bring affordable new medicines to the people who need them in the fastest possible time.

Scale of ambition

Clinical Trials Intelligence will become the standard and essential part of major global clinical trials, and will be valued for its ability to accurately predict issues, delays and cost overruns thereby ensuring faster, more effective trials.

Vision

Improved health outcomes for people with unmet medical need through fast and affordable access to new and promising medicines.

How we will achieve our vision

- Deep insight into the needs of clinical trial sponsors
- Pilot partnership to test and scale; published outcomes
- Tailored, scalable tech solutions to address inefficiencies, security and reduce cost at all stages of the clinical trials process
- Integration into pharma systems using SAAS model - recurring revenue streams

Unique Selling Point

Only Clinical Trials Intelligence uses data analytics and machine learning to monitor and control clinical trial processes to enable the delivery of affordable new medicines faster to the market.

Business Plan Year One

We will acquire pilot partners to test and establish Clinical Trials Intelligence in live clinical trial settings. The value delivered in these deployments will be used to promote the Clinical Trials Intelligence concept, and benefits delivered will be presented at all major clinical trials conferences (e.g. DIA, Clinical Trial Innovation Summit), published to industry forums such as Transcelerate and the Clinical Trials Transformation Initiative (CTTi).

Q2/2021	Q2/2022	Q2/2024
Launch CTi-OEM	1st Revenue Generation	EBITDA Positive
Partnership pilot with a global pharma company	Pilot ends – First License Fees	

← New Pharma Partners identified →

Token Pre-Sale Round

- Introduction
- Problem
- Approach
- Potential
- About us
- Offer
- Projections
- Roadmap
- Team
- Partners
- Information


The Pre-Sale token price is \$0.05c USD in Tier 1 and \$0.075c USD in Tier 2, a discount of 58.3% and 37.5% respectively over the public token sale price of \$0.12c USD. These significant discounts reflect the value ClinTex places on its prospective partners invited to take part in the pre-sale funding rounds.

The pre-sale rounds of the token sale are limited to a maximum of \$1m in Tier 1 and \$2m in Tier 2, between all participants. Accepted currencies are fiat: EUR, GBP, USD, CHF, RMB & KRW, or cryptocurrency: BTC (Bitcoin), ETH (Ethereum), BNB (Binance Coin).

A maximum of 23% of the total CTI token supply will be available in the pre-sale rounds (with the pre-sale discount), giving the participants in this round a considerable financial advantage over the main public sale round (IEO).

The final round of funding will be a token sale offering made to the general public via IEO (“initial exchange offering”), on a prominent cryptocurrency exchange in the last quarter of 2020. In the interests of fairness and to protect value for the retail participants in that round, no private sale contributions can be accepted after the launch of the public sale.

Full details of the token economics (all rounds) of the Clinical Trials Intelligence project are available [here](#).



CTI Token and Token Value

- Introduction
- Problem
- Approach
- Potential
- About us
- Offer
- Projections
- Roadmap
- Team
- Partners
- Information

Primary Token Utility: Licence to Access Clinical Trials Intelligence

To access the Clinical Trials Intelligence platform the client will require a licence, which will be granted by smart contract when a predefined amount of CTI Tokens is staked in the users balance on the Clinical Trials Intelligence platform's integrated wallet. These tokens will need to be purchased on the open market and, once a licence is granted, will remain locked by smart contract in the Clinical Trials Intelligence platform wallet for the duration of the licence period (12 months minimum). This is projected to vastly reduce supply, driving value to the token through scarcity. As ClinTex on-board more clients, tokens are continuously removed from the circulating supply pool.


Brokerage Service for Major Pharmaceutical Clients

To facilitate corporate pharmaceutical clients, a ClinTex subsidiary will offer to act as a brokerage service by taking payment through traditional gateways, which it will then use to purchase CTI from the circulating supply on public exchanges on the clients behalf (ClinTex will charge a fee for this service, which is one of the primary sources of revenue generation for the business).

The graph opposite shows a (modestly) projected % of the total supply that will be removed from the circulating supply as a result of ClinTex business activities, using sales forecast figures (page 14).

- Figures are shown in USD value with an assumption of the CTI price remaining at the token sale value of @\$0.10 – as with any open market this may not be the case (as we expect a significant increase as an outcome of our marketing and business activities), but the graph gives an indicative view of projected share of supply being removed from the market over time.
- Token holders will be the beneficiaries when price is driven up through reduced supply.
- NB: Staked tokens will be publically verifiable by smart contract (locked-up).

ClinTex Clients Staked CTI Tokens as a % of Supply (Projected)



- ClinTex Client Lock-up

CTI Token and Token Value

- Introduction
- Problem
- Approach
- Potential
- About us
- Offer
- Projections
- Roadmap
- Team
- Partners
- Information

Secondary Token Utility

Payments to third party vendors working on the clinical trial (e.g. Hospitals, labs) are made by purchasing CTI tokens, which are then “staked” on Clinical Trials Intelligence, until certain data driven triggers are reached. Again, this reduces supply and increases demand for the token.

Client Acquisition

Further growth potential will derive from ClinTex’s publicising and partnering with some of the biggest names in the pharmaceutical industry, which will naturally lead to keen interest from other pharmaceutical partners, perpetuating and sustaining increases in token value as more licences are sought via the CTI staking model.

Marketing to Industry

ClinTex intend to heavily market to industry through the launch and roll out of Clinical Trials Intelligence’s seven applications, and it is envisioned that demand for licences will experience rapid and expansive growth during this period. As tokens will need to be constantly acquired from the circulating pool each time new Clinical Trials Intelligence access licence is granted, the supply of CTI will reduce significantly as the project matures.

Loyal Base

As the Clinical Trials Intelligence platform will be the first to market with best-in-class clinical trial analytics, it is envisioned that the majority of the customer base will renew their licence after the initial 12-month period, on an on-going basis. Furthermore, large value clients will be incentivised by ClinTex to do so when approaching the end of their licence period. For token holders, this will mean that the staked CTI Tokens for pharma clients will not be returning to the supply pool at the end of the initial 12 month term of the clients licence, and will stay out of circulation indefinitely.


Token Burn

In the event that a pharmaceutical client chooses not to renew their Clinical Trials Intelligence access, the CTI Tokens that were staked for that licence will be returned to ClinTex. As part of our commitment to continuously reduce the CTI supply pool, 20% of those tokens will be destroyed permanently. This token burn will be performed by smart contract and verifiable on the Ethereum public blockchain.

Token Economics

- Introduction
- Problem
- Approach
- Potential
- About us
- Offer**
- Projections
- Roadmap
- Team
- Partners
- Information

CTI Distribution Breakdown



Distribution Dates, Bonus's, Lock-ups & Vest

- Pre-Sale Tier 1 CTI Tokens will come with staggered release 0 – 24 Months. vest period enforced by smart contract (reviewable on the ClinTex Github)
- Pre-Sale Tier 2 CTI Tokens will come with staggered release 0 – 2 Months. vest period enforced by smart contract (reviewable on the ClinTex Github)
- CTI Tokens that are distributed to Partners, Shareholders, and Management Team will all have a 6 – 48 month vest enforced by smart contract (reviewable on the ClinTex Github)
- CTI Tokens reserved for Pharmaceutical Industrial Trials & Testing will be locked until full live net launch and will not be in public circulation (reviewable on the ClinTex Github).

Full details of the token economics (all rounds) of the Clinical Trials Intelligence project are available [here](#).

Financial Projections: Revenue/Sales Forecast

- Introduction
- Problem
- Approach
- Potential
- About us
- Offer
- Projections**
- Roadmap
- Team
- Partners
- Information

Revenue/Sales Forecast In millions of U.S. dollars

	2020	2021	2022	2023	2024	2025	2026	2027	2028
New Annual Licences	0	2	1	2	1	2	2	2	2
New Pay Per User Licences		1	1	2	1	2	2	3	
Total Client Licences	0	2	2	5	8	11	15	19	24
Revenue									
New Customers	–	–	\$0.60	\$0.90	\$0.90	\$0.90	\$1.20	\$1.20	\$1.50
Existing Customers	–	–	–	\$0.60	\$1.50	\$2.40	\$3.30	\$4.50	\$5.70
Total Annual Revenue	–	–	\$0.60	\$1.50	\$2.40	\$3.30	\$4.50	\$5.70	\$7.20


In 2021, ClinTex will on-board two clients initially on a pilot basis to trial the Clinical Trials Intelligence platform on live clinical studies in order to further refine data driven algorithms and further develop the platform for commercial launch.

Once the concept is proven, ClinTex expect to on-board 2 more clients the following year (2022).

Growth is conservatively estimated at an average of 1-2 new annual license clients per year and the on-boarding of between 1 and 3 new clinical trials to the pay-per-use license model per year, post2022.

Full details are available in the ClinTex Clinical Trials Intelligence Business Plan, available on request to qualified investors.

Projected Total Gross Revenue In millions of U.S. dollars



Financial Projections: Costs and Expenses

- Introduction
- Problem
- Approach
- Potential
- About us
- Offer
- Projections**
- Roadmap
- Team
- Partners
- Information

Costs and Expenses

In millions of U.S. dollars

	2020	2021	2022	2023	2024	2025	2026	2027	2028
Employee Compensation and Benefits	–	\$1.48	\$1.48	\$1.48	\$1.48	\$1.48	\$1.48	\$1.48	\$1.48
Marketing, Advertising and Sales	\$0.10	\$0.10	\$0.20	\$0.20	\$0.20	\$0.20	\$0.20	\$0.20	\$0.20
Technology and Communications	–	\$0.25	\$0.25	\$0.25	\$0.25	\$0.25	\$0.30	\$0.30	\$0.30
Legal, Accounting and Professional Fees	–	\$0.10	\$0.10	\$0.10	\$0.10	\$0.10	\$0.10	\$0.10	\$0.10
Operational Expenses (Rent, Utilities etc)	–	\$0.10	\$0.10	\$0.10	\$0.10	\$0.10	\$0.10	\$0.10	\$0.10
Total Annual Costs	\$0.10	\$2.03	\$2.13	\$2.13	\$2.13	\$2.13	\$2.18	\$2.18	\$2.18

→It will cost \$2m - \$3m USD approximately, to reach initial revenue generation (2022).

→It will cost \$6.4m USD approximately, to reach profitability and positive EBITDA. (2024). This development funding is to be acquired through the aforementioned tokensale.


→It is for this reason that the target raise for the token sale is \$7m USD.

→If \$7m is not reached, the soft cap for a viable development plan is \$2m USD. An alternative business and development roadmap (development of CTi-OEM and CTi-CDV only – before revenue generation provides more funding for development), is available on request.

Financial Projections: Profit and Loss

- Introduction
- Problem
- Approach
- Potential
- About us
- Offer
- Projections**
- Roadmap
- Team
- Partners
- Information

Profit and Loss
In millions of U.S. dollars



- Initial development before revenue generation will concentrate on CTi-OEM and CTi-PDA.
- ClinTex expect to generate revenue from 2022, allowing 18 months for the refinement of the CTi-OEM data model, and to allow time to enhance algorithms to augment the predictive power of the CTi-PDA app.
- Growth is expected to be rapid and consistent once Clinical Trials Intelligence becomes established for use in clinical trials.

Pre-Sale Funding Spend

- Introduction
- Problem
- Approach
- Potential
- About us
- Offer
- Projections**
- Roadmap
- Team
- Partners
- Information


Development Spend

- Finalise MVP Development
- Smart Contracts and Smart Contract Design
- Security Audit of all systems and all smart contracts
- Development of Demonstrable Prototype

Marketing Spend

- ClinTex will engage in a vigorous marketing campaign in the lead up to the public round token sale, utilising prominent healthcare & cryptocurrency publications, reviewers and bloggers for community engagement, as well as traditional SEO and online marketing channels.
- ClinTex will engage a top tier cryptocurrency exchange to run the CTI Token sale in a 'launchpad' programme (IEO - 'Initial Exchange Offering').

100% of the pre-sale round funds will be dedicated a demonstrable prototype of the platform and a successful initial token sale event.



Clinical Trials Intelligence Development Roadmap

- Introduction
- Problem
- Approach
- Potential
- About us
- Offer
- Projections
- Roadmap**
- Team
- Partners
- Information

	2018	2019	2020	2021	2022
Q1	Ideation & Research	Development Sprint 2 'Enhancement'	CTi-OEM Prototype Development Private Funding Rounds	CTi-PDA Development	CTi-CDV Development Live Client On-Boarding Begins (1st Revenue)
Q2	Concept Development	Proof of Concept	CTi GUI Development	Migration on-chain of Clinical Trials Intelligence Clinical Data Statistical Summaries Industry Testing Pilot	Migration on-chain of the Clinical Trials Intelligence Data Model and Clinical Trials Intelligence Processing Engine
Q3	Development Sprint 1 'Minimum Viable Product' Whitepaper Published	Strategic Partnerships Agreed	CTi-OEM Development Pre-Sale Token Sale	CTi-PRR Development	CTi-VMM Development
Q4	Industry Consultation on Clinical Trials Intelligence Prototype Core Team Established	CTi Data Model Finalised	Public Token Sale (IEO) Blockchain Verification of Clinical Trials Intelligence Pre-Processing Data	CTi-RBM Development	CTi-SIM Development

The ClinTex Team

Introduction
 Problem
 Approach
 Potential
 About us
 Offer
 Projections
 Roadmap
 — Team
 Partners
 Information

Combining top talent, extensive experience and thought leadership from the pharmaceutical and clinical trial industry, with a unique combination of software, blockchain and analytics development expertise.



[in](#)
 Brendan O'Mainnin
 Chief Executive,
 Founder



[in](#)
 Neill Barron
 Director of Clinical
 Data Analytics,
 Founder



[in](#)
 Ethan Diamant
 Director of
 Clinical Services



[in](#)
 Dr. Samandip Dhese
 Medical Officer



[in](#)
 John McCabe
 Head of Legal
 & Regulatory,
 Founder



[in](#)
 Sean Flanagan
 Head of Business
 Development



[in](#)
 Edward Burke
 Lead Developer



[in](#)
 Roman Tsivka
 Blockchain
 Developer



[in](#)
 Victoria Boychuk
 Developer

Full profile and biography for the team and advisory panel can be found on the ClinTex LinkedIn Group - click individual team members to link.

Who we work with

- Introduction
- Problem
- Approach
- Potential
- About us
- Offer
- Projections
- Roadmap
- Team
- Partners**
- Information



Information

Introduction
Problem
Approach
Potential
About us
Offer
Projections
Roadmap
Team
Partners
- Information

Contact Details

- Pre-Sale Round Frequently Asked Questions [here](#)
- General Information: www.clintex.io
- Enquiries: info@clintex.io

Further Reading

- One Pager [here](#)
- Whitepaper [here](#)
- Technical Paper [here](#)
- ClinTex Promotional Video [here](#)

